Canadian Consensus Conference: The FDA decision on the use of 5ARIs

Authors

  • Laurence Klotz Department of Urology, Sunnybrook Health Science Centre, University of Toronto, Toronto, ON
  • Michael Chetner Division of Urology, University of Alberta Hospital, Edmonton, AB
  • Joseph Chin Division of Urologic Surgery, Western University, London, ON;
  • Tony Finelli Division of Urology/Minimally Invasive Surgery Department of Surgical Oncology Princess Margaret Hospital, Toronto, ON;
  • Neil Fleschner Division of Urology, University Health Network, Toronto, ON;
  • Yves Fradet Department of Urology, Laval University, Quebec, QC;
  • Larry Goldenberg Department of Urologic Sciences, UBC, Vancouver, BC;
  • J. Curtis Nickel Department of Urology, Queen’s University, Kingston, ON;
  • Robert Siemens Department of Urology, Queen’s University, Kingston, ON;
  • Alan So Department of Urologic Sciences, UBC, Vancouver, BC;
  • Linda Sugar Department of Pathology, Sunnybrook Health Science Centre, Toronto, ON;
  • Alexandre Zlotta Department of Urology, Sunnybrook Health Science Centre, University of Toronto, Toronto, ON;
  • Eric Klein Glickman Urological and Kidney Institute, Chairman, Glickman Urological and Kidney Institute, Cleveland, OH;
  • Howard Parnes Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD;
  • David Penson Division of Urology, Vanderbilt University Medical Center; Nashville, TN

DOI:

https://doi.org/10.5489/cuaj.122

Abstract

Downloads

Download data is not yet available.

Author Biographies

Laurence Klotz, Department of Urology, Sunnybrook Health Science Centre, University of Toronto, Toronto, ON

Department of Urology, Sunnybrook Health Science Centre, University of Toronto, Toronto, ON

Michael Chetner, Division of Urology, University of Alberta Hospital, Edmonton, AB

Division of Urology, University of Alberta Hospital, Edmonton, AB

Joseph Chin, Division of Urologic Surgery, Western University, London, ON;

Division of Urologic Surgery, Western
University, London, ON;

Tony Finelli, Division of Urology/Minimally Invasive Surgery Department of Surgical Oncology Princess Margaret Hospital, Toronto, ON;

Division of Urology/Minimally Invasive Surgery Department of Surgical Oncology Princess Margaret Hospital, Toronto, ON;

Neil Fleschner, Division of Urology, University Health Network, Toronto, ON;

Division of Urology, University Health Network, Toronto,

ON;

Yves Fradet, Department of Urology, Laval University, Quebec, QC;

Department of Urology, Laval University, Quebec, QC;

Larry Goldenberg, Department of Urologic Sciences, UBC, Vancouver, BC;

Department of Urologic Sciences, UBC, Vancouver, BC;

J. Curtis Nickel, Department of Urology, Queen’s University, Kingston, ON;

Department of Urology, Queen’s University, Kingston, ON;

Robert Siemens, Department of Urology, Queen’s University, Kingston, ON;

Department of Urology, Queen’s University, Kingston, ON;

Alan So, Department of Urologic Sciences, UBC, Vancouver, BC;

Department of Urologic Sciences, UBC, Vancouver, BC;

Linda Sugar, Department of Pathology, Sunnybrook Health Science Centre, Toronto, ON;

Department of Pathology,

Sunnybrook Health Science Centre, Toronto, ON;

Alexandre Zlotta, Department of Urology, Sunnybrook Health Science Centre, University of Toronto, Toronto, ON;

Department of Urology, Sunnybrook Health Science Centre, University of Toronto, Toronto, ON;

Eric Klein, Glickman Urological and Kidney Institute, Chairman, Glickman Urological and Kidney Institute, Cleveland, OH;

Glickman Urological and Kidney Institute, Chairman, Glickman Urological and Kidney Institute, Cleveland, OH;

Howard Parnes, Prostate and Urologic Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD;

 

 

Prostate and Urologic Cancer Research

Group, Division of Cancer Prevention, National Cancer Institute, Bethesda, MD;

David Penson, Division of Urology, Vanderbilt University Medical Center; Nashville, TN

Division of Urology, Vanderbilt University Medical Center; Nashville, TN

Downloads

Published

2012-12-13

How to Cite

Klotz, L., Chetner, M., Chin, J., Finelli, T., Fleschner, N., Fradet, Y., Goldenberg, L., Nickel, J. C., Siemens, R., So, A., Sugar, L., Zlotta, A., Klein, E., Parnes, H., & Penson, D. (2012). Canadian Consensus Conference: The FDA decision on the use of 5ARIs. Canadian Urological Association Journal, 6(2). https://doi.org/10.5489/cuaj.122

Issue

Vol. 6 No. 2 (2012): CUAJ April

Section

Consensus Statement

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.